GlycoMimetics, Inc. (NASDAQ:GLYC) Q2 2020 Earnings Conference Call - Final Transcript

Jul 31, 2020 • 08:30 am ET


GlycoMimetics, Inc. (NASDAQ:GLYC) Q2 2020 Earnings Conference Call - Final Transcript


Loading Event

Loading Transcript


Good morning, and thank you all for joining GlycoMimetics Corporate Update Conference Call. [Operator Instructions]

I would now like to turn the conference over to Ms. Shari Annes of Investor Relations Group at GlycoMimetics. Please go ahead.

Shari Annes

Thank you. Good morning. Today, we will review our accomplishments and financial results for the second quarter of 2020. The press release we issued this morning is available on the Company's website at, under the Investors tab. This call is being recorded. A dial-in phone replay will be available for 24 hours after the close of the call. The webcast replay will also be available in the Investor Relations section of the Company's website for 30 days.

Joining me on the call today from GlycoMimetics are Rachel King, Chief Executive Officer; Brian Hahn, Senior VP and Chief Financial Officer; and Dr. Helen Thackray; our Senior VP of Clinical Development and Chief Medical Officer.

We will start today's call with comments from Rachel, and after that, Brian will provide an overview of the Company's financial position. We'll then open the call for Q&A, when Dr. Thackray, will be available to respond to your questions.

I'd like to remind you that today's call will include forward-looking statements based on current expectations. Forward-looking statements contained on this call include, but are not limited to, statements about the Company's product candidates, uproleselan, GMI-1359, GMI-1687 and rivipansel, as well as our other pipeline programs, and the potential impact of the ongoing global COVID-19 pandemic on the Company's clinical programs, operations and cash burn.

Such statements represent management's judgment and intention as of today and involve assumptions, risks and uncertainties. GlycoMimetics undertakes no obligation to update or revise any forward-looking statement. For information concerning the risk factors that could affect the Company, please refer to GlycoMimetics' filings with the SEC, which are available from the SEC or on the GlycoMimetics' website.

I'd now like to turn the call over to Rachel.

Rachel K. King

Thank you, Shari, and thank you all for joining our call this morning. Just as I began our last call, I would like to say that the entire team hopes that you and your families remain healthy in the face of the myriad of challenges presented by the COVID-19 pandemic. Here at GlycoMimetics, we've continued our work largely from our homes with minimal disruption to our operations. Although, we are happy to report that our scientists have been able to return to our labs on a staggered basis, all in compliance with CDC and Maryland state guidelines. We're diligently coordinating our activities to maintain ongoing business operations.

Let me begin by saying that the second quarter was a busy and productive one for us. Enrollment continued in our pivotal Phase 3 registration trial, evaluating uproleselan in relapsed/refractory AML. The enrollment rate for the quarter was such that we are maintaining our prior guidance. We expect completion of enrollment in the second half of 2021. We also saw a steady progress in our collaborative multi-center registration trial with the